Evidence map›Paper›PMID 38020574›Full record

ArticleERJ open research2023

A bronchial gene signature specific for severe COPD that is retained in the nose.

Jos van Nijnatten, Alen Faiz, Wim Timens, Victor Guryev, Dirk-Jan Slebos, Karin Klooster, Jorine E Hartman, Tessa Kole, David F Choy, Arindam Chakrabarti and 5 more

Open access · goldAbstract read
In one paragraph

Article in ERJ open research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Blood Biomarkers of Emphysema: What Can They Really Tell Us?American journal of respiratory and critical care medicine · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Jos van NijnattenUniversity of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, the Netherlands.ORCID https://orcid.org/0000-0001-5374-0609
Alen FaizUniversity of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.
Wim TimensUniversity of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, the Netherlands.ORCID https://orcid.org/0000-0002-4146-6363
Victor GuryevUniversity of Groningen University Medical Center Groningen, European Research Institute for the Biology of Ageing, Groningen, the Netherlands.ORCID https://orcid.org/0000-0002-5810-6022
Dirk-Jan SlebosUniversity of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.ORCID https://orcid.org/0000-0001-9555-3422
Karin KloosterUniversity of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.
Jorine E HartmanUniversity of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.ORCID https://orcid.org/0000-0001-8765-9673
Tessa KoleUniversity of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.ORCID https://orcid.org/0000-0002-5176-6300
David F ChoyGenentech Inc., South San Francisco, CA, USA.
Arindam ChakrabartiGenentech Inc., South San Francisco, CA, USA.
Michele GrimbaldestonGenentech Inc., South San Francisco, CA, USA.
Carrie M RosenbergerGenentech Inc., South San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-8189-8822
Huib KerstjensUniversity of Groningen University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, the Netherlands.ORCID https://orcid.org/0000-0001-7705-7927
Corry-Anke BrandsmaUniversity of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, the Netherlands.
Maarten van den BergeUniversity of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.
University Medical Center Groningen · NLUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: A subset of COPD patients develops advanced disease with severe airflow obstruction, hyperinflation and extensive emphysema. We propose that the pathogenesis in these patients differs from mild-moderate COPD and is reflected by bronchial gene expression. The aim of the present study was to identify a unique bronchial epithelial gene signature for severe COPD patients. Methods: We obtained RNA sequencing data from bronchial brushes from 123 ex-smokers with severe COPD, 23 with mild-moderate COPD and 23 non-COPD controls. We identified genes specific to severe COPD by comparing severe COPD to non-COPD controls, followed by removing genes that were also differentially expressed between mild-moderate COPD and non-COPD controls. Next, we performed a pathway analysis on these genes and evaluated whether this signature is retained in matched nasal brushings. Results: We identified 219 genes uniquely differentially expressed in severe COPD. Interaction network analysis identified Conclusions: We found a unique severe COPD bronchial gene signature with key roles for

Identifiers

PMID38020574
PMCPMC10680034
OpenAlexW4386525484

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.